DEA Grants Schedule II Medicine Status To Synthetic Cannabis Drug - Syndros

All cannabis in the United States is classified under Schedule I, the most restrictive [(severely limited or controlled)] classification by the Control Substances Act.

Drugs containing synthetic [(produced by people/not naturally-occurring)] THC, however, was granted Schedule II status by the U.S. Drug EnforcementAgency [(DEA]).

Schedule II status means that the drug can be prescribed by a doctor, but the drug is labeled for a high potential of abuse.

The new drug is made by, a Chandler, Arizona-based pharmaceutical firm called Insys Therapeutics, waited two years for the DEA's approval. The liquid "dronabinol" drug Syndros can now become available in a pharmacy later this year.

Insys interim CEO Dr. Santosh Vetticaden said in a written statement:

"Insys is looking forward to bringing this new drug product to chemotherapy [(using powerful drugs to help cure disease)] patients to help alleviate [reduce] their nausea and vomiting and AIDS patients with anorexia [eating disorder] associated weight loss, respectively," We look forward to interacting with the FDA to finalize labeling and subsequent [later] launch of Syndros in the second half of 2017."

Other cannabis based drugs have achieved Schedule III status, such as Marinol. Liquid dronabinol drugs like Syndros are classified in the more restrictive Schedule II because theoretically [possibly], they could be processed into hash or oil.

This is great news for the drugmaker, which is in hot water over a fentanyl spray Subsys, which it also manufactures. The company is also facing charges from US Attorney General Joseph A. Foster over its drug Subsys.

It's notable that even though the drug maker Insys produces a synthetic [(produced by people/not naturally-occurring)] cannabinoid drug, it has lobbied against cannabis legalization in its home state of Arizona.

Legal, natural medical cannabis in Arizona is a direct competitor for companies like Insys. In some cases, patients tend to prefer other natural options and remedies that replace pharmaceutical drugs with little or no side effects.

#Research #Cannabis #Pharmaceuticals #Pharmaceuticalization #cannabinoids #Dronabinol #Healthcare #naturotherapy

8 views0 comments

Recent Posts

See All

Cannabis Improves Cognitive Performance

Preliminary investigations by medical researchers from McLean Hospital, Harvard Medical School, and Tufts University indicate that pot actually improves cognitive performance. For the study, entitled

Sick of Facebook? MeWe Offers Social Media & Privacy

MeWe has a multitude of different features that allow users to organize and communicate in private CEO Mark Weinstein created the platform with privacy in mind being a huge privacy advocate himself

© 2017 by Living Ultra-Violet Inc. 

Main Office: 1017 Main Campus Drive Suite 2300 Raleigh NC 27616

Mailing Address: 1103 PINEWINDS DR UNIT 108RALEIGH, North Carolina 276036701

  • Facebook App Icon
  • YouTube App Icon
  • Twitter App Icon
  • LinkedIn Social Icon
  • Tumblr Social Icon
  • Google+ Social Icon